BIOS Advisors GP, LLC — SEC Form 4 filings

SEC reporting owner CIK 1813844. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.

Transaction summary — filings shown

Covers all 15 filings on record, filed 2024-01-19 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ACTUATE THERAPEUTICS, INC. (ACTU)Director, 10% owner43 legs · 571,428 sh · $4,499,9966 legs · 49,998 sh · $424,98352
Lantern Pharma Inc. (LTRN)10% owner653 legs · 390,739 sh · $1,613,0186
IN8BIO, INC.10% owner27
COGNITION THERAPEUTICS INC (CGTX)Director, 10% owner34

Form 4 filings — BIOS Advisors GP, LLC

FiledFormIssuerReported transactionsSource
2026-06-224COGNITION THERAPEUTICS INC (CGTX)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund II QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II, LP, BIOS Fund I QP, LP
Grant/award (A): 25,000 @ $0EDGAR
2025-06-304ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, BIOS Equity Partners III, LP
Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0EDGAR
2025-06-204COGNITION THERAPEUTICS INC (CGTX)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II, LP, BIOS Fund II QP, LP
Grant/award (A): 34,000 @ $0EDGAR
2025-06-134Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 moreEDGAR
2025-06-134Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09EDGAR
2025-05-294Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 moreEDGAR
2025-05-074IN8BIO, INC.
jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP
Purchase (P): 1,148,482 (derivative) · Other (J): 574,241 (derivative) · Other (J): 574,241 (derivative)EDGAR
2024-10-114IN8BIO, INC. (INAB)
jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP
Purchase (P): 709,040 (derivative) · Purchase (P): 709,040 (derivative) · Disposition to issuer (D): 574,241 (derivative) · Grant/award (A): 574,241 (derivative)EDGAR
2024-08-204/AACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, BIOS Equity Partners III, LP
Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8EDGAR
2024-08-144ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, BIOS Equity Partners III, LP
Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 moreEDGAR
2024-08-144ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, BIOS Equity Partners III, LP
Holdings only — no transactions reportedEDGAR
2024-06-114COGNITION THERAPEUTICS INC (CGTX)
jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II, LP, BIOS Fund II QP, LP
Grant/award (A): 8,500 @ $0 · Grant/award (A): 8,500 (derivative) @ $0EDGAR
2024-05-284Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Sale (S): 930 @ $6.25 · Sale (S): 1,859 @ $6.33 · Sale (S): 6,944 @ $6.25 · Sale (S): 13,888 @ $6.33 · Sale (S): 2,126 @ $6.25 · Sale (S): 4,253 @ $6.33EDGAR
2024-02-294Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Sale (S): 4,649 @ $4.40 · Sale (S): 6,909 @ $4.85 · Sale (S): 1,832 @ $4.87 · Sale (S): 34,731 @ $4.40 · Sale (S): 51,608 @ $4.85 · Sale (S): 13,686 @ $4.87 · +3 moreEDGAR
2024-01-194Lantern Pharma Inc. (LTRN)
jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP
Option exercise/expiry (X): 7,347 @ $3.13 · Sale (S): 5,475 @ $4.20 · Option exercise/expiry (X): 54,873 @ $3.13 · Sale (S): 40,893 @ $4.20 · Option exercise/expiry (X): 16,801 @ $3.13 · Sale (S): 12,521 @ $4.20 · +3 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1813844 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →